An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.

In the first study, in which 2 doses of ACE527 or placebo were administered 3 weeks apart, there was a borderline significant difference (p = 0.07) in mean disease score between placebo (4.69) and vaccine (3.31) recipients (29% reduction) [ 17 ].

also in 11,409 other papers